Nuvectis Pharma (NVCT) Q3 2026 earnings review
Nuvectis raises cash for new drugs, while older trial slips
Nuvectis Pharma, a developer of pills for rare blood diseases and cancer, reshaped its pipeline and bank account this quarter. The company raised $155 million through stock sales and paid $20 million upfront to license two late-stage drugs from China's Haisco Pharmaceutical. Chief executive Ron Bentsur said the remaining $141 million in cash will fund the business into the second half of 2029.
| Cash and cash equivalents | $140.7M up from $22.2M last quarter |
|---|---|
| Net loss, excluding license fees and stock comp | $5.8M +46% from a year ago by our math |
| NXP200 brain cancer response rate | 40% in 20 high-grade glioma patients |
| Cash runway outlook | Extended into 2H 2029, from 1H 2029 |
⚖️ Verdict: 🟢 Bullish
The story got better because Nuvectis now owns a drug already approved in China and the cash to develop it, rather than relying on a single early cancer trial. Early brain tumor data for its second licensed drug also showed shrinking tumors in 40% of high-grade patients. One caution: the company pushed its legacy lung cancer readout into 2027, and share count jumped 31% in three months.
The question now is whether US regulators will let Nuvectis use Chinese trial data to file its lead blood drug for approval, or demand a new US study. Accepting the Chinese data would put a commercial launch in reach, while a new Phase 3 trial would consume years and much of the new cash. An update on the FDA talks before year-end will settle it.
🐂 Bull Case
Equity Raises Extend Cash Into Late 2029
Nuvectis ended September with $140.7 million in cash, up from $22.2 million in June, after raising $154.5 million to fund its newly licensed drugs. In July the drug developer raised $115.0 million in a public stock offering and added $39.5 million through its at-the-market share sale program, including $37.0 million placed "with a single healthcare dedicated fund".
The company paid $20.0 million upfront to Haisco Pharmaceutical Group for the rights outside China to two clinical compounds, NXP100 and NXP200, plus $1.8 million in milestones for its older cancer drug NXP900. Even after those payments, chief executive Ron Bentsur said the cash will fund operations "into the second half of 2029", which adds six months to the prior plan.
What to watch: quarterly research spending in the first half of 2027 after US trials begin. Staying near $10 million per quarter would keep the three-year cash plan intact without more share sales.
NXP200 Shrinks Brain Tumors in Early Trial
NXP200 is an oral drug designed to cross into the brain and block BRAF, a mutated protein that drives tumor growth. In October, partner Haisco presented Phase 1b trial results in China from 27 patients with recurrent or progressive glioma, a form of brain cancer.
- High-grade glioma response rate: 40.0% across 20 patients, including three complete responses
- Low-grade glioma response rate: 42.9% across 7 patients, including one complete response
- Overall tumor shrinkage: 81.5% of all 27 patients saw their tumors shrink
- Prior BRAF drug patients: two partial responses and one stable disease out of three patients
The responses matter because brain tumors are hard to reach with pills, and activity in patients who already took an older BRAF drug supports wider use. China's drug regulator granted NXP200 Breakthrough Therapy Designation in September, and Nuvectis plans to file to start US testing by year-end.
What to watch: the US regulatory filing for NXP200 by the end of 2026 and expanded Chinese trial data in early 2027. Clearance to begin US trials would allow Nuvectis to test the drug in Western patients.
China Approval Backs Lead Blood Drug Ciprocopan
"The strategic in-licensing of ciprocopan (NXP100, our CFBi) and NXP200 (our paradox-breaker BRAF inhibitor) firmly establishes Nuvectis as a late-stage clinical development company with potential best-in-class assets," chief executive Ron Bentsur said. Ciprocopan is a once-daily pill that blocks Complement Factor B, an immune system protein, to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare disease that destroys red blood cells.
Chinese regulators approved ciprocopan in July 2026 for untreated PNH patients after a Phase 3 trial showed an advantage over Soliris, an injectable treatment. Because ciprocopan is taken once a day rather than twice daily like competing pill Fabhalta, Nuvectis wants to use the Chinese data to speed up US approval.
What to watch: the outcome of US Food and Drug Administration discussions on PNH before the end of 2026. If the agency accepts the Chinese Phase 3 data as the basis for a filing, Nuvectis could avoid a multi-year US trial.
🐻 Bear Case
NXP900 Lung Cancer Readout Pushed to 2027
Before licensing its two Chinese drugs, Nuvectis built its story around NXP900, an oral cancer drug that blocks SRC and YES1 proteins to overcome treatment resistance. Last quarter the company told investors to expect a clinical update from its Phase 1b trial combining NXP900 with Tagrisso in lung cancer by the end of 2026.
This quarter Nuvectis quietly pushed that timeline back, stating that the Phase 1b update is now expected "during the first half of 2027". That marks a second delay for the program, which in the first quarter had aimed for a preliminary readout in the summer of 2026, while the company paid $1.8 million in NXP900 milestones this quarter.
What to watch: Phase 1b combination data from the lung cancer trials in the first half of 2027. Another delay or weak tumor responses would show why management shifted its focus and capital toward the newly licensed Haisco drugs.
New Drug Pipeline Triples Implied Quarterly Burn
Expanding from one early-stage drug to three clinical programs is already lifting Nuvectis's ongoing costs and share count. Reported net loss reached $30.1 million in the third quarter, up from $7.5 million a year ago because of the $20.0 million Haisco license fee and $1.8 million in NXP900 milestones.
- Net loss excluding license fees, milestones and stock compensation: $5.8 million, up 46.4% from $4.0 million a year ago by our math
- General and administrative expenses: $3.7 million, up 82.1% from a year ago on consulting and staffing
- Common shares issued and outstanding: 35.0 million, up 31.2% in a single quarter
- Implied quarterly burn to late 2029: about $11.7 million per quarter by our math, double the current clean loss
Because the $140.7 million cash balance is projected to last about 12 quarters into the second half of 2029, the company's own plan points to quarterly spending roughly doubling as US trials start. That leaves little room for unplanned Phase 3 trials if the FDA requires new US studies.
What to watch: operating loss in the fourth quarter after the one-time license fees roll off. A quarterly loss above $8 million before US trials even start would pressure the 2029 cash target.
👓 Other Themes
AstraZeneca Veteran Hired to Lead Complement Program
In September 2026 Nuvectis hired Dr. Dustin Little as Senior Vice President and Head of its Complement program to run ciprocopan development. Little is a nephrologist who spent ten years at AstraZeneca, most recently leading late-stage kidney, heart and metabolic clinical trials. Chief executive Ron Bentsur said Little is already taking part in FDA talks for PNH and helping pick the next disease targets.
💲 Other KPIs
Current liabilities rose 6.8% from $13.3 million at the end of the second quarter and 22.6% from a year ago. Accrued liabilities jumped to $2.1 million from $0.1 million at year-end, while accounts payable dipped to $5.8 million and employee compensation liabilities held steady at $6.3 million.
Interest earned on cash balances nearly tripled from $0.33 million a year ago and jumped more than fivefold from $0.18 million in the second quarter. The increase came from investing the $154.5 million raised through stock sales in July, which helped offset about asixth of the company's underlying quarterly operating loss.
🔮 Guidance
Raised. The company now expects its $140.7 million cash balance to fund operations into the second half of 2029, six months longer than the plan set after July's public offering. The extra $39.5 million raised through the at-the-market stock facility drove the extension. By our math, funding 12 quarters of operations implies an average burn near $11.7 million per quarter.
Unchanged. Nuvectis still plans to provide an update on its FDA discussions regarding the US regulatory path for ciprocopan in PNH before the end of 2026. The company also plans to submit a US investigational new drug application by year-end to start clinical testing in an additional disease beyond PNH.
Unchanged. The drug developer remains on track to file an investigational new drug application with the FDA by the end of 2026 to begin US clinical trials for its brain-penetrant BRAF blocker. Additional Phase 1b data from partner Haisco's ongoing trial in China, covering more tumor types, will follow in early 2027.
Cut. Management pushed the expected clinical update from the Phase 1b lung cancer combination trials with Tagrisso and Lorbrena from the fourth quarter of 2026 into the first half of 2027. This marks a second delay for the NXP900 readout, which in the first quarter had been slated for a preliminary update in the summer of 2026.
❓ Key Questions
Will the FDA require a new US trial for ciprocopan?
Ciprocopan won approval in China using a Phase 3 study run solely in Chinese patients. Whether the FDA accepts that package for a US marketing filing or demands a new multi-year trial determines both time to market and whether current cash lasts.
Why did the NXP900 lung cancer readout slip again?
The Phase 1b update for NXP900 combined with Tagrisso moved from summer 2026 to late 2026 and now to the first half of 2027. Investors need to know if enrollment slowed or if patients are staying on treatment longer.
Which disease will Nuvectis pick for ciprocopan's year-end filing?
Partner Haisco is already testing ciprocopan in Phase 3 for kidney disease IgAN and Phase 2 for lupus nephritis in China. Naming the first US indication beyond PNH will show how crowded a market Nuvectis is entering.
What future milestone payments are owed to Haisco?
The release details the $20.0 million upfront payment for NXP100 and NXP200, while the company also paid $1.8 million in NXP900 milestones this quarter. The schedule of future regulatory and clinical milestone obligations will determine how much cash remains for trials.